e l f Beauty Inc vs Immunovant Inc. Common Stock — how do they compare? e l f Beauty Inc trades at $105.97 (market cap $6.25B), while Immunovant Inc. Common Stock trades at $30.01 (market cap $6.25B). The key difference: e l f Beauty Inc and Immunovant Inc. Common Stock are close in size by market cap, and e l f Beauty Inc is trading nearer its 52-week high, Immunovant Inc. Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold e l f Beauty Inc for 25 Days and Immunovant Inc. Common Stock for 0 Days on average.
| ELF | IMVT | |
|---|---|---|
Market Cap | $6.25B | $6.25B |
Volume | 1,099,552 | 1,755,411 |
Sector | Consumer Staples | Health |
52-Week High | $144.97 | $44.96 |
52-Week Low | $49.57 | $17.03 |
Typical Hold Time | 25 Days | 0 Days |
Enterprise Value | $6.84B | $5.35B |
Signals from Pluang's Aura AI — not financial advice
ELF trades at $105.03, up 2.18% today, with a bullish technical signal from moving averages and recent earnings beats. The company reported strong revenue growth, with 2025 revenue at $1.31B and net income of $112.09M, though 2026 projections show margin compression. Recent expansion includes the rhode brand launch in Europe via Sephora and marketing initiatives like the 'Mirror Mix' album.
The outlook is mixed: robust growth and analyst support (48% buy ratings) contrast with high valuation (P/E 107.17) and competitive pressures. Key risks include execution of international expansion and sustained profitability amid increased spending. The stock's current price sits above the consensus target of $95.91, suggesting limited near-term upside.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
e.l.f. Beauty is a leading cosmetics company offering high-quality, 100% vegan, and cruelty-free products. It is known for its affordable and prestige-quality makeup and skincare items for a diverse global audience.
Read more on ELF →Immunovant is a clinical-stage immunology company developing therapies for autoimmune diseases. Its pipeline includes anti-FcRn antibody candidates designed for subcutaneous administration.
Read more on IMVT →